Raymond James Upgrades Alnylam Pharmaceuticals to Strong Buy, Maintains Price Target to $420

Benzinga Newsdesk www.benzinga.com Positive 74.8%

Neg 0% Neu 0% Pos 74.8%

Raymond James analyst Martin Auster upgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) from Outperform to Strong Buy and maintains the price target from $420 to $420.